Get the Stockscreener App
1.73
0.57%
-0.01
After Hours:
1.70
-0.03
-1.73%
Milestone Pharmaceuticals Inc stock is traded at $1.73, with a volume of 684.44K.
It is down -0.57% in the last 24 hours and down -12.63% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.74
Open:
$1.74
24h Volume:
684.44K
Relative Volume:
0.14
Market Cap:
$147.34M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.2446
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+3.59%
1M Performance:
-12.63%
6M Performance:
+2.37%
1Y Performance:
-3.89%
1-Day Range:
$1.72
$1.7747
1-Week Range:
$1.61
$1.81
52-Week Range:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.73 | 148.19M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals Grants 419,000 Equity Awards - Intellectia AI
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 133,054 Shares - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Milestone Pharmaceuticals announces U.S. availability of cardamyst - Yahoo Finance
Milestone’s PSVT treatment CARDAMYST now available in US pharmacies By Investing.com - Investing.com Canada
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies - TipRanks
Milestone Pharmaceuticals (MIST) Launches Cardamyst Nasal Spray in U.S. Market - GuruFocus
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Taiwan News
Bull Run: Should I set a stop loss on Milestone Pharmaceuticals IncJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Fed Impact: Will Cohen Circle Acquisition Corp I outperform during market ralliesJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Insider Trends: Is Milestone Pharmaceuticals Inc undervalued by DCF analysisJuly 2025 Reactions & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for Milestone Pharmaceuticals Inc stockM&A Rumor & Growth Focused Investment Plans - baoquankhu1.vn
Earnings Miss: Is Milestone Pharmaceuticals Incs ROIC above industry averageJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
Aug Mood: Should I invest in Milestone Pharmaceuticals Inc before earningsCPI Data & Daily Profit Focused Screening - baoquankhu1.vn
US Stocks Recap: Is Milestone Pharmaceuticals Inc vulnerable to short sellers2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: How does Milestone Pharmaceuticals Inc compare to its peersWeekly Trend Summary & Long-Term Growth Plans - baoquankhu1.vn
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Institutional Moves & Technical Pattern Recognition Alerts - Bộ Nội Vụ
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing - TipRanks
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView
Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Milestone Pharmaceuticals Inc Stock (MIST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bharucha David | Chief Medical Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
113,181 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
41,993 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
49,848 |
| Muller Lorenz | Chief Commercial Officer |
Dec 15 '25 |
Sale |
2.32 |
53,566 |
124,273 |
196,486 |
| Muller Lorenz | Chief Commercial Officer |
Jan 26 '26 |
Sale |
1.93 |
11,180 |
21,577 |
205,406 |
| Hasija Amit | CFO & EVP of Corp. Development |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
91,993 |
| Hasija Amit | CFO & EVP of Corp. Development |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
99,848 |
| Oliveto Joseph | President and CEO |
Dec 15 '25 |
Sale |
2.32 |
133,054 |
308,685 |
450,667 |
| Oliveto Joseph | President and CEO |
Jan 26 '26 |
Sale |
1.93 |
34,523 |
66,629 |
482,744 |
| Oliveto Joseph | President and CEO |
Jan 08 '26 |
Sale |
2.25 |
43,000 |
96,750 |
303,721 |
1.52%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):